Strategic Initiative

Slingshot members are tracking this corporate initiative:

Sanofi Pasteur Signs Research Agreement For Zika Vaccine

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SNY

100%

Additional Information

Additional Relevant Details The agreement also includes Sanofi Pasteur’s production of clinical material in compliance with current GMP (Good Manufacturing Practices) to support phase II testing, optimization of the upstream process to improve production yields, and characterization of the vaccine product. Sanofi Pasteur will also create a clinical development and regulatory strategy.
WRAIR will share data related to the development of immunologic assays designed to measure neutralizing antibody responses following natural infection and vaccination with ZPIV, biologic samples generated during the performance of non-human primate studies, and biologic samples generated during the performance of human safety and immunogenicity studies using ZPIV. WRAIR, the National Institute of Allergy and Infectious Diseases (NIAID)–part of the U.S. National Institutes of Health (NIH), and theBiomedical Advanced Research and Development Authority (BARDA)–part of the Health & Human Services (HHS) Office of the Assistant Secretary of Preparedness and Response–have been coordinating pre-clinical development of the candidate encouraged by new, pre-clinical research conducted by WRAIR and the Beth Israel Deaconess Medical Center[1]. NIAID will sponsor a series of phase 1 ZPIV trials while the technology transfer process is occurring.
http://mediaroom.san...
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jul 06, 2016
Projected Implementation:
Q3, 2016
Relevance Tracked Until:
Q2, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Zika Vaccine